265 related articles for article (PubMed ID: 24477928)
1. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
2. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.
Cohen H; Ben-Hamo R; Gidoni M; Yitzhaki I; Kozol R; Zilberberg A; Efroni S
Breast Cancer Res; 2014 Nov; 16(6):464. PubMed ID: 25410484
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.
Calza S; Hall P; Auer G; Bjöhle J; Klaar S; Kronenwett U; Liu ET; Miller L; Ploner A; Smeds J; Bergh J; Pawitan Y
Breast Cancer Res; 2006; 8(4):R34. PubMed ID: 16846532
[TBL] [Abstract][Full Text] [Related]
4. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
6. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
Jiang YZ; Yu KD; Bao J; Peng WT; Shao ZM
Cancer Res; 2014 Jul; 74(13):3399-407. PubMed ID: 24924774
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
8. GATA3 somatic mutations are associated with clinicopathological features and expression profile in TCGA breast cancer patients.
Afzaljavan F; Sadr AS; Savas S; Pasdar A
Sci Rep; 2021 Jan; 11(1):1679. PubMed ID: 33462316
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
10. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D; Cheang M; Nielsen T
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):365-73. PubMed ID: 18268121
[TBL] [Abstract][Full Text] [Related]
11. The molecular diversity of Luminal A breast tumors.
Ciriello G; Sinha R; Hoadley KA; Jacobsen AS; Reva B; Perou CM; Sander C; Schultz N
Breast Cancer Res Treat; 2013 Oct; 141(3):409-20. PubMed ID: 24096568
[TBL] [Abstract][Full Text] [Related]
12. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.
Bong PN; Zakaria Z; Muhammad R; Abdullah N; Ibrahim N; Emran NA; Syed Hussain SN
Malays J Pathol; 2010 Dec; 32(2):117-22. PubMed ID: 21329183
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
14. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
[TBL] [Abstract][Full Text] [Related]
15. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
[TBL] [Abstract][Full Text] [Related]
16. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
[TBL] [Abstract][Full Text] [Related]
17. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
18. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
